Halozyme

Pharma

AstraZeneca inks $1.35B deal for subcutaneous cancer drugs

AstraZeneca signed the Alteogen collaboration despite an escalating patent dispute around the Korean company's ALT-B4 subcutaneous drug delivery tech.

Angus Liu Mar 17, 2025 10:55am

Merck, Halozyme dig in for patent fight over injectable Keytruda

Mar 6, 2025 11:18am

Roche doubles down with subcutaneous FDA nod for MS star Ocrevus

Sep 13, 2024 1:50pm

J&J can reduce Darzalex royalty payments, a tribunal voted

Apr 8, 2022 9:55am

Argenx's subcutaneous efgartigimod matches IV sibling in phase 3

Mar 22, 2022 7:55am